High affinity, bioavailable 3-amino-1,4-benzodiazepine-based γ-secretase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 22, 2003, Pages 4143-4145

  Owens, Andrew P ^a   Nadin, Alan ^a   Talbot, Adam C ^a   Clarke, Earl E ^a   Harrison, Timothy ^a   Lewis, Huw D ^a   Reilly, Michael ^a   Wrigley, Jonathan D J ^a   Castro, José L ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; ENZYME INHIBITOR; GAMMA SECRETASE INHIBITOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ISOMER; METHYLATION; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

EID: 0242317272     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.07.031     Document Type: Article

References (13)

1. Hardy J., Selkoe D.J. Science. 297:2002;353 Moore C.L., Wolfe M.S. Exp. Opin. Ther. Pat. 9:1999;135 Jhee S., Shiovitz T., Crawford A.W., Cutler N.R. Exp. Opin. Invest. Drugs. 10:2001;593 Conde S. Exp. Opin. Ther. Pat. 12: 2002;503 Dominguez D.I., De Strooper B., Annaert W. Amyloid. 8:2001;124.
2. Hardy J., Selkoe D.J. Science. 297:2002;353 Moore C.L., Wolfe M.S. Exp. Opin. Ther. Pat. 9:1999;135 Jhee S., Shiovitz T., Crawford A.W., Cutler N.R. Exp. Opin. Invest. Drugs. 10:2001;593 Conde S. Exp. Opin. Ther. Pat. 12: 2002;503 Dominguez D.I., De Strooper B., Annaert W. Amyloid. 8:2001;124.
3. Hardy J., Selkoe D.J. Science. 297:2002;353 Moore C.L., Wolfe M.S. Exp. Opin. Ther. Pat. 9:1999;135 Jhee S., Shiovitz T., Crawford A.W., Cutler N.R. Exp. Opin. Invest. Drugs. 10:2001;593 Conde S. Exp. Opin. Ther. Pat. 12: 2002;503 Dominguez D.I., De Strooper B., Annaert W. Amyloid. 8:2001;124.
4. Hardy J., Selkoe D.J. Science. 297:2002;353 Moore C.L., Wolfe M.S. Exp. Opin. Ther. Pat. 9:1999;135 Jhee S., Shiovitz T., Crawford A.W., Cutler N.R. Exp. Opin. Invest. Drugs. 10:2001;593 Conde S. Exp. Opin. Ther. Pat. 12: 2002;503 Dominguez D.I., De Strooper B., Annaert W. Amyloid. 8:2001;124.
5. Hardy J., Selkoe D.J. Science. 297:2002;353 Moore C.L., Wolfe M.S. Exp. Opin. Ther. Pat. 9:1999;135 Jhee S., Shiovitz T., Crawford A.W., Cutler N.R. Exp. Opin. Invest. Drugs. 10:2001;593 Conde S. Exp. Opin. Ther. Pat. 12: 2002;503 Dominguez D.I., De Strooper B., Annaert W. Amyloid. 8:2001;124.
6. Churcher I., Ashton K., Butcher J.W., Clarke E.E., Harrison T., Lewis H.D., Owens A.P., Teall M.R., Williams S., Wrigley J.D. J. Bioorg. Med. Chem. Lett. 13:2003;179.
7. Churcher, I.; Nadin, A. J.; Owens, A. P. PCT Int. Appl. WO 0230912, 2002.
8. Nadin A., Sánchez López J.M., Owens A.P., Howells D.M., Talbot A.C., Harrison T. J. Org. Chem. 68:2003;2844.
9. 50 data shown are the geometric mean of minimum of three independent results. Cell viability is measured by a colorimetric cell proliferation assay (CellTitre 96™ AQ assay, Promega).
10. Evans D.A., Ennis M.D., Mathre D.J. J. Am. Chem. Soc. 104:1982;1737.
11. All compounds shown containing an α-methyl substituent are single diastereomers with an (S) stereo conformation at the C3 benzodiazepine centre.
12. Ishiyama T., Murata M., Miyaura N. J. Org. Chem. 60:1995;7508.
13. Castro Pineiro, J. L.; Churcher, I.; Guiblin, A. R.; Harrison, T.; Kerrad, S.; Madin, A.; Nadin, A. J.; Owens, A. P.; Sparey, T. J.; Teall, M. R.; Williams, S. PCT Int. Appl. WO 0190084, 2002.